$CLDX,STATE STREET CORP Total Shares: 8,561,225 Ha
Post# of 23091
Posted On: 04/09/2016 8:30:02 AM
$CLDX,STATE STREET CORP Total Shares: 8,561,225 Has Stake in Celldex Therapeutics, Inc. (CLDX)
http://www.statestreet.com/home.html
STATE STREET CORP Total Shares: 8,561,225 Has Stake in Celldex Therapeutics, Inc. (CLDX)
Posted by paymon on Apr 8th, 2016 // No Comments
Celldex Therapeutics logo
STATE STREET CORP
Total Shares:
8,561,225
disclosed that they own 8.7% of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in a Form 13G disclosure that was filed with the Securities and Exchange Commission (SEC) on Friday, April 8th. The investor owns 8,561,225 shares of the stock worth $40,323,370. The filing is available through Edgar at this link.
A number of other hedge funds and other institutional investors have also modified their holdings of the company. DekaBank Deutsche Girozentrale increased its position in shares of Celldex Therapeutics by 1.0% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 50,100 shares of the biopharmaceutical company’s stock valued at $808,000 after buying an additional 500 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Celldex Therapeutics by 1.0% in the fourth quarter. The Manufacturers Life Insurance Company now owns 64,690 shares of the biopharmaceutical company’s stock worth $1,015,000 after buying an additional 662 shares in the last quarter. Bedell Frazier Investment Counseling LLC raised its position in Celldex Therapeutics by 9.0% in the fourth quarter. Bedell Frazier Investment Counseling LLC now owns 65,236 shares of the biopharmaceutical company’s stock worth $1,023,000 after buying an additional 5,411 shares in the last quarter. Tocqueville Asset Management L.P. raised its position in Celldex Therapeutics by 54.9% in the fourth quarter. Tocqueville Asset Management L.P. now owns 73,400 shares of the biopharmaceutical company’s stock worth $1,151,000 after buying an additional 26,000 shares in the last quarter. Finally, ProShare Advisors LLC raised its position in Celldex Therapeutics by 10.7% in the fourth quarter. ProShare Advisors LLC now owns 93,666 shares of the biopharmaceutical company’s stock worth $1,469,000 after buying an additional 9,072 shares in the last quarter.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded down 0.42% during trading on Friday, reaching $4.69. The company had a trading volume of 1,957,980 shares. The company has a 50-day moving average of $4.98 and a 200-day moving average of $10.93. The firm’s market capitalization is $462.92 million. Celldex Therapeutics, Inc. has a 52-week low of $2.96 and a 52-week high of $30.28.
Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, February 25th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.02. During the same period in the prior year, the business earned ($0.36) EPS. The firm earned $1.80 million during the quarter, compared to the consensus estimate of $0.80 million. The company’s revenue for the quarter was up 21.1% compared to the same quarter last year. Analysts expect that Celldex Therapeutics, Inc. will post ($1.33) EPS for the current fiscal year.
CLDX has been the topic of several analyst reports. Wedbush downgraded Celldex Therapeutics from an “outperform” rating to a “neutral” rating and set a $4.00 target price on the stock. in a research note on Monday, March 7th. Jefferies Group downgraded Celldex Therapeutics from a “buy” rating to a “hold” rating and decreased their price target for the stock from $31.00 to $4.00 in a report on Monday, March 7th. Zacks Investment Research cut shares of Celldex Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 4th. Guggenheim downgraded shares of Celldex Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, March 7th. Finally, HC Wainwright reduced their target price on shares of Celldex Therapeutics from $25.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, March 8th. Seven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $20.00.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
(0)
(0)
http://www.statestreet.com/home.html
STATE STREET CORP Total Shares: 8,561,225 Has Stake in Celldex Therapeutics, Inc. (CLDX)
Posted by paymon on Apr 8th, 2016 // No Comments
Celldex Therapeutics logo
STATE STREET CORP
Total Shares:
8,561,225
disclosed that they own 8.7% of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in a Form 13G disclosure that was filed with the Securities and Exchange Commission (SEC) on Friday, April 8th. The investor owns 8,561,225 shares of the stock worth $40,323,370. The filing is available through Edgar at this link.
A number of other hedge funds and other institutional investors have also modified their holdings of the company. DekaBank Deutsche Girozentrale increased its position in shares of Celldex Therapeutics by 1.0% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 50,100 shares of the biopharmaceutical company’s stock valued at $808,000 after buying an additional 500 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Celldex Therapeutics by 1.0% in the fourth quarter. The Manufacturers Life Insurance Company now owns 64,690 shares of the biopharmaceutical company’s stock worth $1,015,000 after buying an additional 662 shares in the last quarter. Bedell Frazier Investment Counseling LLC raised its position in Celldex Therapeutics by 9.0% in the fourth quarter. Bedell Frazier Investment Counseling LLC now owns 65,236 shares of the biopharmaceutical company’s stock worth $1,023,000 after buying an additional 5,411 shares in the last quarter. Tocqueville Asset Management L.P. raised its position in Celldex Therapeutics by 54.9% in the fourth quarter. Tocqueville Asset Management L.P. now owns 73,400 shares of the biopharmaceutical company’s stock worth $1,151,000 after buying an additional 26,000 shares in the last quarter. Finally, ProShare Advisors LLC raised its position in Celldex Therapeutics by 10.7% in the fourth quarter. ProShare Advisors LLC now owns 93,666 shares of the biopharmaceutical company’s stock worth $1,469,000 after buying an additional 9,072 shares in the last quarter.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded down 0.42% during trading on Friday, reaching $4.69. The company had a trading volume of 1,957,980 shares. The company has a 50-day moving average of $4.98 and a 200-day moving average of $10.93. The firm’s market capitalization is $462.92 million. Celldex Therapeutics, Inc. has a 52-week low of $2.96 and a 52-week high of $30.28.
Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, February 25th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.02. During the same period in the prior year, the business earned ($0.36) EPS. The firm earned $1.80 million during the quarter, compared to the consensus estimate of $0.80 million. The company’s revenue for the quarter was up 21.1% compared to the same quarter last year. Analysts expect that Celldex Therapeutics, Inc. will post ($1.33) EPS for the current fiscal year.
CLDX has been the topic of several analyst reports. Wedbush downgraded Celldex Therapeutics from an “outperform” rating to a “neutral” rating and set a $4.00 target price on the stock. in a research note on Monday, March 7th. Jefferies Group downgraded Celldex Therapeutics from a “buy” rating to a “hold” rating and decreased their price target for the stock from $31.00 to $4.00 in a report on Monday, March 7th. Zacks Investment Research cut shares of Celldex Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 4th. Guggenheim downgraded shares of Celldex Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, March 7th. Finally, HC Wainwright reduced their target price on shares of Celldex Therapeutics from $25.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, March 8th. Seven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $20.00.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
(0)
(0)
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'